Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/31756
Title: Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
Authors: Chacra, Antonio Roberto [UNIFESP]
Tan, G. H.
Apanovitch, A.
Ravichandran, S.
List, J.
Chen, R.
CV181-040
Universidade Federal de São Paulo (UNIFESP)
Cebu Doctors Univ Hosp
Bristol Myers Squibb Co
Issue Date: 1-Sep-2009
Publisher: Wiley-Blackwell
Citation: International Journal of Clinical Practice. Malden: Wiley-Blackwell Publishing, Inc, v. 63, n. 9, p. 1395-1406, 2009.
Abstract: Aims:Assess the efficacy and safety of saxagliptin added to a submaximal sulphonylurea dose vs. uptitration of sulphonylurea monotherapy in patients with type 2 diabetes and inadequate glycaemic control with sulphonylurea monotherapy.Methods and patients:A total of 768 patients (18-77 years; HbA(1c) screening >= 7.5 to < 10.0%) were randomised and treated with saxagliptin 2.5 or 5 mg in combination with glyburide 7.5 mg vs. glyburide 10 mg for 24 weeks. Blinded uptitration glyburide was allowed in the glyburide-only arm to a maximum total daily dose of 15 mg. Efficacy analyses were performed using ANCOVA and last-observation-carried-forward methodology.Results:At week 24, 92% of glyburide-only patients were uptitrated to a total glyburide dose of 15 mg/day. Saxagliptin 2.5 and 5 mg provided statistically significant adjusted mean decreases from baseline to week 24 vs. uptitrated glyburide, respectively, in HbA(1c) (-0.54%, -0.64% vs. +0.08%; both p < 0.0001) and fasting plasma glucose (-7, -10 vs. +1 mg/dl; p = 0.0218 and p = 0.002). the proportion of patients achieving an HbA(1c) < 7% was greater for saxagliptin 2.5 and 5 mg vs. uptitrated glyburide (22.4% and 22.8% vs. 9.1%; both p < 0.0001). Postprandial glucose area under the curve was reduced for saxagliptin 2.5 and 5 mg vs. uptitrated glyburide (-4296 and -5000 vs. +1196 mg center dot min/dl; both p < 0.0001). Adverse event occurrence was similar across all groups. Reported hypoglycaemic events were not statistically significantly different for saxagliptin 2.5 (13.3%) and 5 mg (14.6%) vs. uptitrated glyburide (10.1%).Conclusion:Saxagliptin added to submaximal glyburide therapy led to statistically significant improvements vs. uptitration of glyburide alone across key glycaemic parameters and was generally well tolerated.
URI: http://repositorio.unifesp.br/handle/11600/31756
ISSN: 1368-5031
Other Identifiers: http://dx.doi.org/10.1111/j.1742-1241.2009.02143.x
Appears in Collections:Em verificação - Geral

Files in This Item:
File Description SizeFormat 
WOS000268853300025.pdf330.13 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.